# CJC-1295 Research Literature — A page-by-page reading > A close reading of the published CJC-1295 research: the Jetté 2005 identification paper, the Teichman 2006 Phase 1 study, the Alba 2006 knockout mouse rescue, and the terminated NCT00267527 Phase 2 program. Four anchor papers, one halted Phase 2, and the mechanism that holds them together. ## The short version CJC-1295 has four published research anchors: the 2005 lab paper that identified it, one Phase 1 study in healthy adults, one mouse-model rescue study, and a terminated Phase 2 trial that never published results. The Phase 1 data, from Teichman and colleagues in 2006, are the only source of human pharmacokinetic numbers for the compound. The Phase 2 was stopped after a participant death that an independent review judged unrelated to the drug — but the development program never restarted. Everything else in the published record is forensic, mechanistic, or anti-doping work. The clinical evidence base is deliberately narrow and bounded, and this page reads each anchor paper closely rather than extending beyond what was measured. ## The identification paper: Jetté et al., 2005 The compound that came to be called CJC-1295 was first characterized as a 'long-lasting GRF analog' in *Endocrinology* in 2005 [1]. The work, from the ConjuChem laboratory team that would later sponsor the human trials, screened a series of human GRF(1-29) maleimide derivatives for their ability to form an albumin bioconjugate after subcutaneous injection and to activate the GRF receptor on the rat anterior pituitary. The lead candidate from that screen produced a four-fold increase in growth hormone area-under-curve over two hours compared with the unconjugated peptide, and bioactivity persisted beyond 72 hours in circulation. That candidate was designated CJC-1295. The paper established the mechanistic premise: a maleimide-modified GRF(1-29) bound covalently to albumin retained GHRH-receptor agonism while gaining a dramatically extended pharmacokinetic profile. ## The human Phase 1 study: Teichman et al., 2006 The single most informative human paper on CJC-1295 is Teichman and colleagues in the *Journal of Clinical Endocrinology and Metabolism*, March 2006 [2]. Two randomized, placebo-controlled, double-blind ascending-dose trials were conducted in healthy adults aged 21 to 61, over 28 and 49 days respectively. Dose cohorts examined single subcutaneous injections at 30, 60, 125, and 250 micrograms per kilogram, with separate cohorts receiving multiple weekly or biweekly doses. The central findings are tightly stated. After a single injection, mean plasma growth hormone rose in a dose-dependent fashion by two- to ten-fold and remained elevated for six days or more. Mean plasma IGF-1 rose 1.5- to three-fold and remained elevated for nine to eleven days. The estimated plasma half-life of CJC-1295 itself was 5.8 to 8.1 days. In multiple-dose cohorts, mean IGF-1 levels remained above baseline for up to 28 days. The investigators reported no serious adverse reactions and described the compound as 'safe and relatively well tolerated, particularly at doses of 30 or 60 micrograms per kilogram.' This is the only published human study to provide quantitative pharmacokinetic and pharmacodynamic data on CJC-1295 in healthy adults. Every subsequent claim about half-life, GH elevation, or IGF-1 duration traces back, directly or indirectly, to this paper. ## The knockout-mouse rescue: Alba et al., 2006 Alba and colleagues, in the *American Journal of Physiology — Endocrinology and Metabolism* in 2006, used a GHRH-knockout mouse model to ask whether CJC-1295 could restore normal growth in animals genetically incapable of producing endogenous GHRH [4]. The investigators administered 2 micrograms per injection at 24-, 48-, or 72-hour intervals for five weeks, beginning at one week of age. Once-daily dosing restored body weight and length to wild-type levels; less frequent dosing produced partial rescue. Treatment increased somatotroph cell proliferation in the pituitary and raised GH messenger RNA. Body composition — lean mass and adiposity — remained normal across the treated cohorts. The Alba paper is the strongest single piece of preclinical evidence that CJC-1295 can drive the GH/IGF-1 axis productively in a deficient model. It is also, importantly, a developmental-growth study in young mice, not a body-composition study in adult humans; the inferential distance from this paper to claims about adult body composition is large. ## The terminated Phase 2 program: NCT00267527 ConjuChem advanced CJC-1295 to a Phase 2 trial in HIV-associated visceral obesity in December 2005 [3]. The study (ClinicalTrials.gov identifier NCT00267527) was a multicenter, randomized, placebo-controlled, double-blind trial planned to enroll 192 participants across sites in North and South America. The intervention was weekly subcutaneous CJC-1295. In October 2006 the study was terminated. A participant had died of an acute coronary event approximately two hours after their eleventh weekly dose. An independent clinical review concluded that the most likely cause was pre-existing undiagnosed coronary artery disease with plaque rupture, and judged the event unrelated to study drug. The sponsor did not restart the program. Primary outcome data — including any planned visceral-adipose-tissue change — were never published in the peer-reviewed literature. This is the structural reason that, twenty years later, there is no published human efficacy trial for CJC-1295. The compound's clinical promise was inferred — reasonably — from the PK profile, but the trial that would have demonstrated body-composition outcomes was halted before it could read out. ## Adjacent mechanistic and forensic work Three additional papers round out the literature. Ionescu and Frohman, 2006, showed in human pharmacodynamic substudies that CJC-1295 raises trough growth hormone roughly 7.5-fold while preserving the natural pulsatile pattern of secretion — a profile mechanistically distinct from exogenous recombinant GH, which suppresses endogenous pulsatility [5]. Sackmann-Sala and colleagues, 2009, applied serum proteomics to samples from healthy young men one week post-CJC-1295 and identified five differentially expressed serum proteins, including a linear correlation between an immunoglobulin/albumin-fragment spot and IGF-1 [6]. Henninge and colleagues, 2010, working from the Norwegian Doping Control Laboratory, identified CJC-1295 as the active substance in an unknown peptide pharmaceutical preparation by LC-HRMS/MS sequence determination [11]. The paper demonstrated that illicit CJC-1295 was already circulating outside any clinical oversight by the late 2000s. Thomas and colleagues, 2024, published validated nano-LC orbitrap mass spectrometry methods for CJC-1295 and related GHRH analog detection in athlete urine in compliance with WADA technical requirements [10]. Together these papers establish that detection is solved, the abuse channel exists, the receptor pharmacology is well-characterized, and the biomarker signature of GH/IGF-1 axis activation is identifiable in serum. What remains unestablished, from the published record, is durable efficacy and long-term safety in any adult human population. --- An independent reading of publicly available CJC-1295 research — not a clinic, not a vendor, not a treatment recommendation.